Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory
Update: 2025-10-14
Description
In this episode:
What the FDA warning really means for Wegovy, Ozempic, and Zepbound users
Why an OAI classification matters — and how it could affect GLP-1 access
How the FDA oversight system protects patients (and where it fails)
Why compounded GLP-1 medications exist in the first place
The bigger picture: access, safety, and patient rights
What the FDA warning really means for Wegovy, Ozempic, and Zepbound users
Why an OAI classification matters — and how it could affect GLP-1 access
How the FDA oversight system protects patients (and where it fails)
Why compounded GLP-1 medications exist in the first place
The bigger picture: access, safety, and patient rights
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
